Illiasul Ibad/X
Aug 24, 2025, 18:21
Illiasul Ibad: How Clinical Trials Revolutionized ANCA Vasculitis Treatment from Cyclophosphamide to Rituximab
Illiasul Ibad, Rheumatologist at Christian Medical College, Vellore, shared a post on X:
“How clinical trials revolutionized ANCA vasculitis maintenance – from cyclophosphamide to rituximab, this is the journey of evidence, one trial at a time.
Facts. Timelines. Game-changers.
A must-read for every physician, rheumatologist, nephrologist, pulmonologist, and ophthalmologist. This is how science shaped the standard of care.
Special thanks to George Deva Raja for the image design.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS